Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | LTA4H | P09960 | 2/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.58 |
| ▸ | MMP2 | P08253 | 4/20 | 0.56 |
| ▸ | MMP3 | P08254 | 2/20 | 0.56 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 2/20 | 0.52 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL492168 | 0.91 | CACNA1B (0.66) | HRH3MMP2MMP3CACNA1BALDH1A1 | |
| SCHEMBL491881 | 0.87 | KDM4E (0.64) | HRH3MMP2MMP3CACNA1BALDH1A1 | |
| SCHEMBL21601511 | 0.84 | MMP2 (0.52) | MMP2MMP3CACNA1BALDH1A1MAPT | |
| SCHEMBL5276493 | 0.82 | KDM4E (0.56) | CACNA1BALDH1A1CACNA1HKDM4ESMN1; SMN2 | |
| SCHEMBL492266 | 0.81 | MCHR1 (0.60) | HRH3LTA4HMMP2MMP3ALDH1A1 | |
| SCHEMBL12460736 | 0.81 | CACNA1B (0.53) | HRH3LTA4HMMP2MMP3CACNA1B | |
| SCHEMBL29658837 | 0.81 | CHRNB2 (0.59) | HRH3LTA4HKEAP1NFE2L2ALDH1A1 | |
| SCHEMBL781198 | 0.81 | CHRNB2 (0.59) | HRH3LTA4HKEAP1NFE2L2ALDH1A1 | |
| SCHEMBL7986752 | 0.81 | ALDH1A1 (0.66) | HRH3MMP2MMP3ALDH1A1MAPT | |
| SCHEMBL2958271 | 0.81 | HRH3 (0.59) | HRH3LTA4HKEAP1NFE2L2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3044221-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INST OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2018-02-21 | — | — | EP | disclosed |
| US-9611223-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2017-04-04 | — | — | US | disclosed |
| US-20160221953-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH ROYAL CANCER HOSPITAL (THE) (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20090203940-A1 | Method for preparing 4-[2-(dimethylamino)ethoxy]benzylamine as itopride-hydrocloride salt mediate | IL-YANG PHARM. CO., LTD. (KR) | 2009-08-13 | — | — | US | disclosed |
| US-20090177008-A1 | NOVEL PROCESS FOR SYNTHESIS OF ITOPRIDE AND ITS NOVEL INTERMEDIATE N-(4-HYDROXYBENZYL)- 3,4-DIMETHOXYBENZAMIDE | CADILA PHARMACEUTICALS LTD. (IN) | 2009-07-09 | — | — | US | disclosed |
| US-7432293-B2 | Heterocyclic compounds useful as Nurr-1 activators | NOVARTIS AG (CH) | 2008-10-07 | — | — | US | disclosed |
| EP-1527042-B1 | METHOD FOR PRODUCING AMINOALKOXY BENZYLAMINES AND AMINOALKOXY BENZONITRILES AS INTERMEDIATES | BASF SE (DE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007074386-A9 | A NOVEL PROCESS FOR SYNTHESIS OF ITOPRIDE AND IT’S NOVEL INTERMEDIATE-N-(4-HYDROXYBENZYL)-3,4-DIMETHOXYBENZAMIDE | KHAMAR BAKULESH MAFATLAL (IN) | 2007-12-06 | — | — | WO | disclosed |
| EP-1771408-A4 | METHOD FOR PREPARING 4-[2-(DIMETHYLAMINO)ETHOXY]BENZYLAMINE AS ITOPRIDE HYDROCLORIDE SALT MEDIATE | IL YANG PHARM CO LTD (KR) | 2007-08-29 | — | — | EP | disclosed |
| US-7256312-B2 | Method for producing aminoalkoxy benzylamines and aminoalkoxy benzonitriles as intermediates | BASF AKTIENGESELLSCHAFT (DE) | 2007-08-14 | — | — | US | disclosed |
| WO-2004072050-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS NURR-1 ACTIVATORS | NOVARTIS AG (CH) | 2004-08-26 | — | — | WO | disclosed |
| EP-1423120-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20040087588-A1 | Parp inhibitors | ICOS CORPORATION | 2004-05-06 | — | — | US | disclosed |
| WO-2004013082-A2 | METHOD FOR PRODUCING AMINOALKOXY BENZYLAMINES AND AMINOALKOXY BENZONITRILES AS INTERMEDIATES | BASF AKTIENGESELLSCHAFT (DE) | 2004-02-12 | — | — | WO | disclosed |
| WO-2003015785-A1 | 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF | ICOS CORPORATION (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-0511165-B1 | Dicetopyrrolopyrrole compounds | CIBA GEIGY AG (CH) | 1996-08-14 | — | — | EP | disclosed |
| US-5424452-A | A red pigment having at least one substituted pyrrolyl or indolyl-alkoxy group; paints, printing inks; colorfastness, heat and radiation resistance, gloss, weatherproofing | CIBA-GEIGY CORPORATION (US) | 1995-06-13 | — | — | US | disclosed |
| US-5342955-A | Excellent rheological and coloristic properties in paint system and in printing ink | CIBA-GEIGY CORPORATION (US) | 1994-08-30 | — | — | US | disclosed |
| US-5200528-A | Enhanced coloristic and rheological properties, paints, inks | CIBA-GEIGY CORPORATION (US) | 1993-04-06 | — | — | US | disclosed |
| EP-0511165-A2 | Dicetopyrrolopyrrole compounds | CIBA-GEIGY AG (CH) | 1992-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087588-A1 | Parp inhibitors | PARP1, PARP2, PARP11 | HRH3 2457/4885LTA4H 4496/4885KEAP1 312/4885 |
| US-20090203940-A1 | Method for preparing 4-[2-(dimethylamino)ethoxy]benzylamine as itopride-hydrocloride salt mediate | KCNN1, HCN4, KCNN2 | HRH3 34/4885LTA4H 835/4885KEAP1 1102/4885 |
| US-20160221953-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | TNKS, TNKS2, PARP1 | HRH3 3582/4885LTA4H 4224/4885KEAP1 497/4885 |
| US-20090177008-A1 | NOVEL PROCESS FOR SYNTHESIS OF ITOPRIDE AND ITS NOVEL INTERMEDIATE N-(4-HYDROXYBENZYL)- 3,4-DIMETHOXYBENZAMIDE | KCNMB4, QDPR, HCN4 | HRH3 1237/4885LTA4H 325/4885KEAP1 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.